NFKB1 and breast carcinoma: Th17-related inflammation may also lead to upregulation of IL17B and its receptor (IL17RB), another member of the IL-17 cytokine family, in malignant mammary epithelial cells, thereby inducing activation of the ERK1/2, NF-κB and Bcl-2 pathways and promoting inflammation and breast cancer progression [21].